Answers are grounded in this paper and cite their sources.
Shows that dopexamine boosts cardiac output without worsening ventilation-perfusion distribution or pulmonary shunt in anesthetized patients, indicating preserved gas exchange.
We studied the effects of the beta2-adrenoceptor and DA1-receptor agonist dopexamine on ventilation perfusion (VA/Q) distribution in anesthetized, paralyzed patients (n = 17) undergoing major abdominal surgery. Intrapulmonary shunt (QS/QT) (percentage of cardiac output [CO]), perfusion of low VA/Q areas (percentage of CO), ventilation of high VA/Q areas (percentage of total ventilation [VE]), and dead space ventilation [percentage of VE]) were calculated from the retention/excretion data of six inert gases. In the control state, QS/QT was 11% +/- 9% (mean +/- SD) and little perfusion of low VA/Q areas (3% +/- 4%) was observed. Infusion of 1.0 micro g [center dot] kg-1 [center dot] min-1 dopexamine had no effect on QS/QT and low VA/Q areas despite an increased CO (7.7 +/- 2.2 L/min versus 6.2 +/- 1.2 L/min; P < 0.01). PaO (2) increased from 15.5 +/- 5.6 kPa (116 +/- 42 mm Hg) to 17.3 +/- 6.3 kPa (130 +/- 47 mm Hg) (P < 0.05). Infusion of 2.0 micro g [center dot] kg-1 [center dot] min-1 dopexamine further increased CO to 8.4 +/- 2.7 L/min (P < 0.01) without alterations of QS/QT, perfusion of low VA/Q areas, and PaO2. We concluded that dopexamine (1.0 micro g [center dot] kg-1 [center dot] min (-1) and 2.0 micro g [center dot] kg-1 [center dot] min-1) has no adverse effects on VA/Q relationships and QS/QT in anesthetized, paralyzed patients. Implications: The IV administration of vasoactive drugs can improve oxygen delivery to different organ systems but may impair pulmonary gas exchange. In anesthetized, paralyzed patients, we studied the effects of beta2-adrenoceptor and DA1-receptor agonist dopexamine on ventilation perfusion distribution. Dopexamine (1.0 micro g [center dot] kg-1 [center dot] min-1 and 2.0 micro g [center dot] kg-1 [center dot] min-1) improved cardiac output and oxygenation without alterations of intrapulmonary shunt. (Anesth Analg 1998;86:314-9)
No takes yet. Share an insight, caveat, or question.
Hachenberg et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: